SO, here is the real deal. After only 98,000 news sources and over 4,300 blogs picked up the news that this was…
“THE FIRST EVER CARDIAC STEM CELL INJECTION!!”
…there was FINALLY a retraction. Turns out, the procedure was unique only because they used “a pure population of stem cells, the c-kit-positive cells.”
[I liken this to inventing a car that runs on hamburgers and printing the headline: FIRST EVER CAR INVENTED! and then retracting it later with: “oops, we meant, first car to run on hamburgers.”]
You have to ask yourself…Was this accident (in light of the thousands of cardiac patients already treated with stem cells around the world and the many US and international cardiac stem cell clinical trials detailed in previous articles), truly an accident or an attempt at hyping a story with the knowledge that NO ONE would see the retraction…NO ONE except for those reading my blog, that is!
I’ll keep em honest if at all possible and continue to give you the straight dope ’cause, after all….who else will? -dg
p.s. there are 731 scholarly articles listed under the search terms “c-kit-positive stem cell heart”, 884 under “c-kit-positive stem cell cardiac.” I don’t have time to check them all but who wants to bet there have been multiple studies in the world using c-kit-positive injections and maybe some in the US as well?
Correction to Earlier Release From Jewish Hospital and University of Louisville
LOUISVILLE, Ky., July 24 /PRNewswire-USNewswire/ — In today’s announcement regarding the use of stem cells in the treatment of heart failure, we failed to make a critical distinction. Louisville researchers and physicians have performed the world’s first phase-one FDA-approved clinical trial using “c-kit-positive” adult cardiac stem cells to treat heart disease. The clinical trial is being conducted by a team of University of Louisville physicians at Jewish Hospital, in collaboration with Dr. Piero Anversa and his team at the Brigham and Women’s Hospital in Boston.
Following the press conference Roberto Bolli, Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology and Director of UofL’s Institute for Molecular Cardiology, stated, “Another clinical trial is being conducted at another facility. The difference between what we have done and what another institute nationally has done is that we have injected a pure population of stem cells, the c-kit-positive cells. The other institution injected cardiosphere-derived cells, which are a mixture of primitive and partially differentiated cells, complicating the recognition of the actual therapeutic cell. Our study involves a specific, well-characterized population of undifferentiated cells: the c-kit-positive cardiac stem cells are self-renewing, clonogenic and multipotent, which are the fundamental properties of stem cells.”
This is a small, but distinct difference than the procedure performed last month in California.
We regret any misunderstanding or confusion.